CSI Market
Sign In | Register

Cellular Biomedicine Group Inc (CBMG) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CBMG quarterly Cash Flow →
Tracking cash flow results across Cellular Biomedicine Group Inc to Dec 31 2015 helps illustrate how Dec 31 2019's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
12 Months 		(Dec 31 2018) (Dec 31 2017) (Dec 31 2016) (Dec 31 2015)
Operating Activities
Income-49.98
Depreciation & amortization5.64
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.19
Share-based Compensation4.06
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Value Of Stock Received For Services-
Loss On Extinguishment Of Debt-
Deferred Compensation Arrangement With Individual Compensation Expense-
Amortization Of Deferred Charges-
Loss On Disposal Of Investments-
Equity Method Investment Other Than Temporary Impairment-
Impairment Of Investments-
Interest Expense0.48
Interest Expense Deposits From Other Federal Home Loan Banks-0.50
Income taxes0.00
Realized Investment Gains (Losses), Total0.00
Accounts Receivable-0.15
Increase (Decrease) in Accounts Payable1.17
Increase (Decrease) in Accrued Liabilities0.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.83
Other Working Capital-1.29
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.15
Discontinued operations0.00
Net Cash flow from Operating Activities-39.65
Investing Activities
Capital Expenditures-11.54
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Assets-
Payments For Purchase Of Other Assets-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Assets, Investing Activities0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.15
Discontinued operations0.00
Net Cash Flow from Investing Activities-11.40
Financing Activities
Short-term debt Net14.55
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock17.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net-0.47
Advances From Affiliate-
Repayment Of Advances From Affiliate-
Stock Repurchased During Period Value-1.04
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities30.49
Effect of exchange rate on cash flow0.19
Discontinued operations15.44
Free Cash Flow-51.19
Total Cash Flow-20.37
4 historic quarters locked

Sign in to unlock the full Cellular Biomedicine Group Inc cash flow history.

Sign In Create Free Account

About CBMG Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License